Protalix BioTherapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2014 | $912.0K | $-55.6M | $54.8M |
| FY2015 | — | $10.9M | $76.4M |
| FY2016 | — | $-10.0M | $63.3M |
| FY2017 | — | $-29.5M | $51.2M |
| FY2018 | — | $-52.9M | $37.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2014 | $912.0K | $-55.6M | $54.8M |
| FY2015 | — | $10.9M | $76.4M |
| FY2016 | — | $-10.0M | $63.3M |
| FY2017 | — | $-29.5M | $51.2M |
| FY2018 | — | $-52.9M | $37.8M |